SAN DIEGO & BRISTOL, Tenn. & TIVERTON, R.I., Sep 08, 2010 (BUSINESS WIRE) — Santarus, Inc. (NASDAQ: SNTS), S2 Therapeutics, Inc. and VeroScience LLC today announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize Cycloset(R) (bromocriptine mesylate) tablets in the U.S. Cycloset is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as mono-therapy and in combination with other oral antidiabetic agents. Santarus expects to commercially launch Cycloset in November 2010.
Cycloset is the first FDA-approved drug for patients with type 2 diabetes to target the activity of dopamine, a chemical messenger between neurons within the central nervous system. The precise mechanism by which Cycloset improves glycemic control is unknown, but basic science research suggests that the active agent in Cycloset acts to reset aberrant central neuro-metabolic control of peripheral metabolism towards normal in diabetic patients resulting in a reduction in insulin resistance. In clinical studies, once daily, morning administration of Cycloset improved glycemic control, as demonstrated by a significant reduction in mean HbA1c (0.4 – 0.9%, data on file), and improved postprandial glucose levels without increasing plasma insulin concentrations in patients with type 2 diabetes.
Cycloset improves glycemic control without increasing cardiovascular event risk. The safety profile of Cycloset was assessed in a one-year, Phase III safety study that included 2,054 patients in the Cycloset arm versus 1,016 patients in the placebo arm to evaluate overall and cardiovascular safety parameters. Cycloset did not increase the incidence of a composite cardiovascular endpoint relative to placebo. The prespecified composite cardiovascular endpoint for Cycloset-treated patients was significantly reduced by 42% when compared to patients receiving placebo, thus the treatment was found to be cardiovascular safe. Based on the demonstrated safety profile of Cycloset, the FDA did not require a post-approval cardiovascular safety study to specifically evaluate the cardiovascular safety of Cycloset in higher-risk populations. Overall serious adverse events occurred in 8.5% of the Cycloset-treated patients and 9.6% of the placebo-treated patients.
“Given its novel biological activity, positive impact on glucose control and cardiovascular safe profile, we believe Cycloset represents an attractive new option for the treatment of patients with type 2 diabetes,” said Gerald T. Proehl, president and chief executive officer of Santarus. “We view Cycloset as an excellent product to leverage our sales organization, with complete overlap of the endocrinologists and primary care physicians we call on for GLUMETZA(R).”
Charles P. Sutphin, co-chairman, president and chief executive officer of S2 Therapeutics said, “We are excited about the distribution and license agreement with Santarus for Cycloset and the strategic fit with its organization. We look forward to working with Santarus to commercialize Cycloset in the U.S.”
Anthony H. Cincotta, PhD, president and chief scientific officer of VeroScience said, “Having worked on the research and clinical development of Cycloset for decades, it is gratifying to know that very soon the medical community will have access to this first and only centrally acting dopamine agonist antidiabetic agent that has the potential to be an important new therapy for patients with type 2 diabetes.”
Cycloset was the first and to date, the only drug for the treatment of type 2 diabetes to be approved subsequent to the FDA’s Guidance to Industry titled, “Diabetes Mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes” that met the recommendations in this guidance relative to study design and outcome with demonstrated cardiovascular safety pre-approval. This FDA Guidance, issued in December 2008, requires clinical studies to demonstrate that medicines for diabetes do not increase cardiovascular risk, especially in patients with existing or potential heart problems.
